Anthem Biosciences share price
NSE: ANTHEMBSE: 544449Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹800.75.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹45,804 Cr226th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 21 Sep 2026
- 79.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 Sep 2026
- 15.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.25%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 21 Sep 2026
- 18.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 21 Sep 2026
- 21.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 Sep 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,35,89649.5% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 21 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹418 Crdown 31.55%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹120 Crdown 36.79%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 28.7%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Jun 2025Filed 13 Aug | Sep 2025Filed 9 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 21 Sep | Jun 2026Filed 21 Jul |
|---|---|---|---|---|---|
| Revenue | 540 | 550 | 423 | 611 | 418 |
| Net profit | 136 | 173 | 93 | 190 | 120 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 25.1% | 31.5% | 21.9% | 31.1% | 28.7% |
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- CRDMOCRDMO, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,773 Cr83.5%
- Speciality IngredientsSpeciality Ingredients, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹352 Cr16.5%
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 69% of 237 trading days since Nov 2025.
At or below today's level on 88% of 247 trading days over the last year.
Mutual funds holding it
155 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 69 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 65
- CutCut. Funds that held fewer shares than at the end of the month before.
- 28
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 56
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 4
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 74,00,111 | 0.59% | ₹635.4 Cr |
 SBI Midcap FundSBI Mutual Fund | 43,18,200 | 1.59% | ₹370.8 Cr |
 Axis ELSS Tax Saver FundAxis Mutual Fund | 29,22,400 | 0.83% | ₹250.9 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 24,50,000 | 0.75% | ₹210.4 Cr |
| SBI MNC FundSBI Mutual Fund | 22,00,000 | 2.96% | ₹188.9 Cr |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 18,80,000 | 2.75% | ₹161.4 Cr |
| Axis Midcap FundAxis Mutual Fund | 18,52,294 | 0.47% | ₹159.0 Cr |
 UTI Mid Cap FundUTI Mutual Fund | 16,00,000 | 1.15% | ₹137.4 Cr |
 Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 15,79,081 | 0.89% | ₹135.6 Cr |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 12,91,629 | 3.17% | ₹110.9 Cr |
Peers and competitors
Pharmaceuticals & Biotechnology, 222 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Anthem Biosciences in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 25 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.00 |
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
Jul 2026
Anthem Biosciences share price by year
Each calendar year to 2025.Anthem Biosciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 651.50 | – | 864.50 | 628.25 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 795.00 | 817.80 | 783.35 | 812.80 | 799.04 | 5,35,896 | 49.5% |
| 22 Oct 2026 | 798.00 | 808.85 | 789.00 | 800.75 | 800.66 | 2,45,422 | 53.8% |
| 21 Oct 2026 | 808.45 | 819.60 | 795.00 | 805.55 | 803.39 | 5,01,179 | 55.0% |
| 19 Oct 2026 | 822.15 | 825.80 | 802.85 | 808.50 | 814.98 | 3,60,867 | 54.7% |
| 16 Oct 2026 | 840.30 | 843.15 | 816.60 | 822.15 | 824.16 | 5,99,949 | 60.2% |
| 15 Oct 2026 | 850.00 | 854.80 | 824.85 | 842.10 | 840.26 | 8,52,912 | 57.2% |
| 14 Oct 2026 | 865.00 | 868.60 | 845.05 | 847.75 | 858.06 | 5,45,121 | 61.4% |
| 13 Oct 2026 | 877.95 | 877.95 | 848.00 | 870.15 | 857.45 | 3,98,675 | 50.0% |
| 12 Oct 2026 | 862.30 | 889.00 | 862.30 | 883.55 | 879.07 | 3,21,651 | 71.7% |
| 9 Oct 2026 | 872.55 | 880.20 | 842.20 | 862.30 | 866.19 | 1,87,250 | 44.4% |
About Anthem Biosciences
Anthem Biosciences is a contract research, development and manufacturing organisation (CRDMO) based in Bengaluru. Its registered and corporate office is at Bommasandra Industrial Area, Bangalore. It works with global biotech and pharmaceutical companies on both new chemical entities and biological entities, through an integrated platform that spans discovery, development and commercial manufacturing.
Its services cover small and large molecules, including peptides, oligonucleotides, antibody-drug conjugates (ADCs), RNAs and lipids. Its capabilities also include enzymes and high-potency active pharmaceutical ingredients (APIs). Manufacturing platforms include fermentation, biocatalysis and flow chemistry. A second area of business is speciality ingredients.
The company has four manufacturing units in Karnataka, India, one of them under construction. Unit I is at Bommasandra, Bangalore, and Units II and III are at Harohalli. Unit III, called NeoAnthem, includes peptide manufacturing. Unit IV, a 30-acre project also at Harohalli, is under construction. Customers are spread across 44 or more countries, and a partnership with Davos Pharma gives the company market access to biotech companies in the United States. It has one wholly owned subsidiary, Neoanthem Lifesciences Private Limited, which was incorporated in 2020 and is registered at the same Bommasandra address as the parent.
The company was incorporated in 2006. Its initial public offering was made entirely as an offer for sale, and its shares were listed on the BSE and the NSE in July 2025.
- Legal name
- Anthem Biosciences Limited
- NSE symbol
- ANTHEM
- BSE code
- 544449
- ISIN
- INE0CZ201020
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jul 2025
- Face value
- ₹2
- CIN
- U24233KA2006PLC039703
- Corporate identity number, the registrar of companies' code for it